Rapid selection of sotrovimab escape variants in SARS-CoV-2 Omicron infected immunocompromised patients.

ABSTRACT:

Background

Monoclonal antibodies (mAb) targeting SARS-CoV-2 are predominantly less effective against Omicron variants. Immunocompromised patients often experience prolonged viral shedding and are therefore at increased risk for viral escape mutations, when mAbs are used as monotherapy.

Methods

In an observational, prospective cohort, 57 patients infected with Omicron variants receiving sotrovimab alone or in combination with remdesivir were followed. The study endpoints were a decrease in SARS-CoV-2-RNA <106 copies/ml in nasopharyngeal swabs at day 21 and the emergence of resistance mutations at days 7, 14, and 21 after sotrovimab administration. All SARS-CoV-2 samples were analyzed by whole-genome sequencing, individual variants within the quasispecies were subsequently qua

SUBMITTER: Gliga S 

PROVIDER: S-EPMC9619606 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature